ready to grow

Woman in tech accelerator launches first Houston cohort

DivInc has launched its new female-focused accelerator and named its first cohort. Photo via Getty Images

DivInc, an Austin-based accelerator for women and people of color, announced today that it has launched its first Women in Tech HTX cohort in partnership with female-focused co-working space SheSpace.

The nine women-led companies will join DivInc's 11th cohort and the first to operate out of Houston. Founders will receive $10,000 in non-dilutive funding upon completion of a 12-week curriculum, which includes in-depth workshops that aim to help the founders "make a year's worth of progress in just three months," Amanda Moya, DivInc’s Houston program director, said in a statement.

According to DivInc, the aim of the accelerator is to support more female-led startups in the Houston area (which the company says it has seen an emergence of in the last two years) and connect them with its network of VCs.

Founders will be paired with mentors from Microsoft and Google to support their next phases of development. DivInc and SheSpace will also provide stipends for founders in need of childcare assistance.

A committee consisting of representatives from Mercury, Artemis Fund, Microsoft, and several other partners helped select the group of founders considering market size, scalability, industry need, and other factors.

Members of the fall cohort include:

Weekly workshops will take place at SheSpace, an all-women coworking space developed by Stephanie Tsuru that opened in the Heights in 2020. The accelerator is also supported by Houston Houston partners J.P. Morgan Chase & Co., Verizon, The Ion and Mercury.

DivInc will introduce the accepted companies at a happy hour on Thursday, Sept. 22 at The Ion. Those interested in attending can RSVP online.

"With several of these companies coming from outside of Texas, we’re looking forward to the founders making organic connections and learning more about what Houston has to offer," Moya added.

SheSpace will host the accelerator. Image via shespacehtx.com

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted